IFCT at the 2016 ESMO Annual Meeting
The French Cooperative Thoracic Intergroup (IFCT) will be attending the annual meeting of the European Society of Medical Oncology (ESMO) which will be held on October 7-11, 2016 in Copenhagen.
The results of the IFCT-1003 LADIE Trial will be presented during a poster session :
IFCT-1003 LADIE trial : Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC (J. Mazières) Abstract
Click here to download the poster
Click here to view all IFCT studies selected for oral or poster presentations.
IFCT at the 2016 ASCO Annual Meeting
The French Cooperative Thoracic Intergroup (IFCT) will be attending the annual meeting of the American Society of Clinical Oncology (ASCO) which will be held on June 3-7, 2016 in Chicago.
The results of four studies sponsored by IFCT will be presented :
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.
IFCT-1001 CHIVA trial : A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC).
View abstract - Download Poster
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) : The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
View abstract - Download Poster
Pathological central review of 290 thymic epithelial tumors (TET) : The national network RYTHMIC experience.
IFCT at the 2015 ASCO Annual Meeting
The French Cooperative Thoracic Intergroup (IFCT) will be, once again, attending the Annual Meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29th to June 2nd 2015 in Chicago.
The results of two studies sponsored by IFCT will be presented :
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial (ORAL SESSION):
IFCT is pleased to report that in this French multicenter randomized phase 3 trial, bevacizumab addition to pemetrexed/cisplatin provides a significantly longer survival in patients with Malignant Pleural Mesothelioma, with acceptable toxicity, making this triplet a new treatment paradigm. Full data has been submitted to the American Society of Clinical Oncology 2015 Annual Meeting.
Click here to view the abstract
Click here to read the trial results presented at ASCO 2015 #ASCO2015
A randomized, double-blind, placebo-controlled Phase II-III multi-centre study to evaluate the effect of adjuvant pazopanib (GW786034) versus placebo on post-surgical disease-free survival in patients with stage I non small cell lung cancer and tumor size equal or inferior to 5 cm (POSTER DISCUSSION SESSION).
Click here to view the abstract
Download the poster at the bottom of this page
One trial in progress will also be presented during a poster session:
All abstracts part of 2015 ASCO Annual Meeting are available at: http://abstracts.asco.org/
Created in 1999, IFCT is a multidisciplinary group of experts sponsoring clinical research to improve the survival and quality of life of patients with lung cancer.
IFCT is a non-profit association and is therefore strongly committed to conducting independent studies. The main goals of the association are:
- To facilitate the development of clinical and translational research in Thoracic Oncology
- To provide lifelong learning for oncology professionals and share information on Thoracic Oncology
- To foster epidemiologic research and prevention studies
- To promote the evaluation of clinical practice in Thoracic Oncology
IFCT projects are coordinated by a Clinical Research Unit accredited by the National Cancer Institute (INCa) and the National League Against Cancer.
A technology platform enables experts to perform translational research (immunohistochemistry staining automates, slides scanner and multiheads microscope).
IFCT in Figures
Nearly 9,000 patients included in 28 studies
300 centers across France
19 people - Clinical Research Unit staff
IFCT research activity
IFCT is involved in several types of clinical trials that evaluate new active treatments, different combinations of existing treatments or new approaches to surgery or radiation therapy.
Click here for more information about clinical trials currently performed by IFCT
IFCT studies are presented in greatest international congresses, e.g. ASCO and ESMO, and also published in the leading peer-reviewed oncology journals (Lancet, Journal of Clinical Oncology,…).
Click here for more information about IFCT publications
IFCT is strongly committed to conducting independent studies. IFCT scientific activities are funded by contributions, donations, and support of various sources of public and industrial funds. Protocols and research programmes are supported by contracts with institutional or industrial partners. The accounts are monitored by a chartered accountant and annually subjected to the approval of the general assembly, after being audited by the statutory auditor.
The association is managed by a Board of Directors made up of 13 members elected by the general assembly from among the members of the association. The Board of Directors nominates a Scientific Committee that is responsible for elaborating and managing scientific projects. This committee takes advice from the working groups. IFCT clinical trials can be the result of an internal suggestion or emanate from an outside proposal. The relevance of the project is analyzed by the Scientific Committee. The decision whether or not to conduct a trial is entrusted to the Board of Directors.
Members of the Scientific Committee are selected based on their scientific competence and expertise. Each member of the Scientific Committee must provide an annual declaration of any direct or indirect interests they have in the pharmaceutical industry (e.g. membership of an Advisory board).